TAG :愛滋病治療單株抗體UB-421

View More
UBI集團訊息
18082021
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure

United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure
View More
UBI集團訊息
18082021
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准

聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准
View More
UBI集團訊息
24082020
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection

They have received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) to conduct a Phase 3 clinical trial with UB-421

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
View More
UBI集團訊息
24082020
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行

UB-421應用於治療多重抗藥性HIV感染病患之3期臨床試驗今日獲中國國家藥品監督管理局(NMPA)核准執行

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行
View More
UBI集團訊息
05082020
聯生藥抗體新藥UB-421皮下注射(SC)劑型獲台灣衛福部核准進行臨床I期試驗

台灣衛生福利部食品藥物管理署(TFDA)已核准其開發中抗體新藥UB-421之皮下注射(SC)劑型在HIV-1感染、但尚未接受任何藥物治療 (treatment naive)的患者上進行I 期臨床試驗。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥抗體新藥UB-421皮下注射(SC)劑型獲台灣衛福部核准進行臨床I期試驗
View More
UBI集團訊息
29042020
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection

They have received Investigational New Drug (IND) approval from Taiwan FDA to conduct a Phase 3 clinical trial with UB-421 in patients with multi-drug resistant (MDR) HIV-1 infection.

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection
View More
UBI集團訊息
29042020
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行

UB-421應用於治療多重抗藥性(multi-drug resistant (MDR)HIV感染病患之3期臨床試驗已獲台灣FDA核准執行

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行
View More
UBI集團訊息
22032020
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients

They have received Investigational New Drug (IND) approval from China National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to evaluate UB-421’s efficacy

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
View More
UBI集團訊息
22032020
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請

中國國家藥品監督管理局(NMPA)核准其治療HIV-1感染抗體新藥UB-421之II 期功能性治癒概念驗證臨床試驗的申請

UBI group

愛滋病治療單株抗體UB-421
more
中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請
View More
UBI集團訊息
09122019
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」

聯合生物製藥(股)公司(聯生藥)今日宣布，其愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」
View More
UBI集團訊息
30112019
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421

The signing of a clinical trial agreement with NIH/NIAID for their sponsorship of a clinical trial with UB-421 for treatment of multi-drug resistant (MDR) HIV infection.

UBI group

愛滋病治療單株抗體UB-421
more
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
View More
UBI集團訊息
30112019
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議

NIH/NIAID將贊助UB-421應用於治療多重藥抗藥性(Multiple Drug Resistance，MDR)HIV感染之臨床試驗。

UBI group

愛滋病治療單株抗體UB-421
more
聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議

我們有話要説 (一)：請各界持續支持各式國產疫苗的開發、厚植國力

我們有話要說 (二)：病毒不斷突變也不怕！聯亞生技廣譜新冠疫苗可協助解決病毒變異及疫苗頻繁接種的安全與有效性！

我們有話要說 (三)：良好的保護力絕不能只看中和抗體！全球科學界大聲疾呼正視T細胞免疫記憶能力之重要性 –強力T細胞免疫才能提供免於感染各種變異病毒株的廣譜保護力–

我們有話要說(四)：聯亞生技UB-612新冠疫苗追加劑試驗數據展現強效且廣譜的的B細胞和T細胞免疫能力; 期盼政府支持UB-612加速審查，共同為國家與人民福祉創造多贏

United BioPharma Received IND Approvals from Taiwan FDA and China NMPA for two Phase 2 Studies with UB-421 Monotherapy and in Combination with Chidamide to Evaluate the Application in HIV Functional Cure

聯生藥評估UB-421對HIV功能性治癒的療效之二期臨床試驗IND獲准

United BioPharma Received IND Approval from China NMPA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection

聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲中國NMPA核准執行

聯生藥抗體新藥UB-421皮下注射(SC)劑型 獲台灣衛福部核准進行臨床I期試驗

United BioPharma Received Approval from TFDA for a Phase 3 Trial with UB-421 in Patients with Multi-Drug Resistance (MDR) HIV-1 infection

聯生藥抗體新藥UB-421用於多重抗藥性愛滋病患3期臨床試驗獲台灣FDA核准執行

United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients

中國NMPA核准聯生藥治療愛滋病抗體新藥UB-421 之一項評估減少病患HIV病毒儲存庫的臨床II期試驗申請

聯生藥愛滋病治療抗體新藥UB-421榮獲第十六屆國家新創獎年度續獎「新創精進獎」

United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421

聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於 多重抗藥性HIV感染病患之臨床試驗協議

聯生藥抗體新藥UB-421皮下注射(SC)劑型獲台灣衛福部核准進行臨床I期試驗

聯生藥與美國NIH/NIAID簽署合作執行UB-421 應用於多重抗藥性HIV感染病患之臨床試驗協議